Is Varex Imaging Corporation (NASDAQ:VREX) a Buy? The Stock Reported Less Sellers

The stock of Varex Imaging Corporation (NASDAQ:VREX) registered a decrease of 8.37% in short interest. VREX’s total short interest was 1.25 million shares in June as published by FINRA. Its down 8.37% from 1.37M shares, reported previously. With 357,800 shares average volume, it will take short sellers 4 days to cover their VREX’s short positions.

The stock increased 3.24% or $0.91 during the last trading session, reaching $29.02. About 375,408 shares traded or 21.10% up from the average. Varex Imaging Corporation (NASDAQ:VREX) has declined 21.70% since June 11, 2018 and is downtrending. It has underperformed by 26.13% the S&P500.

Varex Imaging Corporation designs and makes medical X-ray tubes and image processing solutions. The company has market cap of $1.11 billion. The firm offers X-ray imaging components, such as tubes, digital flat panel detectors, and other image processing solutions, which are key components of X-ray imaging systems. It has a 87.67 P/E ratio. The Company’s components are used in medical imaging, as well as in industrial and security imaging applications.

More notable recent Varex Imaging Corporation (NASDAQ:VREX) news were published by: which released: “Varex Imaging is Now Oversold (VREX) – Nasdaq” on October 04, 2018, also with their article: “Varex To Present At The Jefferies 2019 Healthcare Conference – PRNewswire” published on May 21, 2019, published: “VREX or BSX: Which Is the Better Value Stock Right Now? – Nasdaq” on May 30, 2019. More interesting news about Varex Imaging Corporation (NASDAQ:VREX) were released by: and their article: “Hedge Funds Have Never Been This Bullish On Inspire Medical Systems, Inc. (INSP) – Yahoo Finance” published on May 03, 2019 as well as‘s news article titled: “Varex To Showcase New X-Ray Imaging Products At European Congress Of Radiology – PRNewswire” with publication date: February 21, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.